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Objectives:  Methamphetamine users may suffer from a range of co-morbid 
psychiatric disorders.  Predictors of treatment outcome in substance dependence 
may include both such co-morbidity and readiness for change. The nature of the 
relationship between psychiatric co-morbidity and readiness for change has not been 
systematically studied. Therefore, this study aimed to assess the prevalence and 
patterns of psychiatric disorders in individuals dependent on methamphetamine; 
determine whether there is a relationship between such co-morbidity and readiness 
for change; and identify factors associated with readiness for change in this group. 
Methods: Sixty adult patients with a diagnosis of methamphetamine dependence 
and no co-morbid medical disorder were consecutively recruited from three drug 
rehabilitation centres. The Mini-International Neuropsychiatric Interview (MINI) was 
used to obtain the diagnosis of Methamphetamine dependence. Each volunteer 
completed a Socio-demographic Questionnaire and Severity of Dependence Scale 
(SDS). Psychiatric co-morbidity was evaluated using the Structured Clinical Interview 
for DSM-IV Axis I disorders (SCID), and Readiness for change (Motivation) was 
measured with SOCRATES 8D (Stages of Change Readiness and Treatment 
Eagerness Scale). 
Results: Almost all (96.7%) the respondents were of the ‘coloured’ race, mostly 
males (71.7%) with more than half (55.0%) being 25-34 years of age. The 
prevalence of psychiatric co-morbidity was 38.3%. The most prevalent psychiatric 
disorders were mood disorders (18.3%), psychotic disorders (13.3%) and anxiety 
disorders (6.7%). More than half of the respondents (60%) were at the stage of 
Taking steps. Female gender and having religious affiliation were associated with 
increased Recognition of the drug problem (p = 0.04 and 0.002 respectively). Having 
alternative non-drug related leisure activities was associated with reduced 
ambivalence to change (p = 0.002). Also, treatment duration correlated negatively 
with Ambivalence (p = 0.01). An inverse relationship was observed between the 
duration of methamphetamine use and the stage of Taking steps (p = 0.02). 
Psychiatric co-morbidity adversely affected recognition of the drug problem (p= 0.01) 















Conclusion: Psychiatric disorders are highly prevalent among individuals dependent 
on methamphetamine. These impair ability to recognise the drug problem but do not 
seem to affect the other stages of change. There is a need to review the current 
admission policy into rehabilitation centres and incorporate an integrated treatment 
approach addressing both substance use disorders and psychiatric co-morbidity for 
methamphetamine using population. Efforts aimed at management of leisure time 
and substitution with non-drug related activities may bolster readiness for change 

































Six years after the initial reports of increase in Methamphetamine use in the Western 
Cape , data from treatment centres showed that methamphetamine was the most 
common primary substance of abuse in Cape Town (SACENDU, 2010).This 
increase in methamphetamine use  contributed to increased demand and need for 
psychiatric intervention in the Province (Plüddemann et al, 2009).  
Methamphetamine users do suffer from a range of psychiatric disorders (Glasner-
Edwards et al, 2010; Zweben et al, 2004). The presence of such co-occurring 
psychiatric disorders may adversely affect their response to the treatment of 
substance use disorder. Data from the United States indicates that 
methamphetamine-dependent adults with psychiatric co-morbidity had poorer 
treatment and functional outcomes (Glasner-Edwards et al, 2010). However, there is 
relatively little data on co-morbidity in methamphetamine users from low and middle 
income countries.  
While it is clear that co-morbidity impacts negatively on treatment outcomes, the 
mechanism underlying this relationship is unclear. One possibility is that co-morbidity 
impacts on readiness for change. Although readiness for change plays an important 
role in predicting outcomes (Joe et al, 1998), the relationship between Co-morbidity 
and Readiness for change has not been well studied to date.  
Therefore, this study aims to assess the prevalence and patterns of co-morbid 
psychiatric disorders in a sample of methamphetamine users in a low to middle 















and readiness for change; and identify factors associated with readiness for change 
































2.1 METHAMPHETAMINE – AN OVERVIEW: 
2.1.1 The ‘Drug’- Methamphetamine 
Methamphetamine, a derivative of amphetamine, has more pronounced effects on 
the central nervous system than amphetamine (Yoshida, 1997). It possesses a 
methyl group which increases its lipid solubility and permeability of the blood-brain 
barrier (Kish, 2008; Cruickshank and Dyer, 2009). These physical properties lead 
potentially to increased potency and toxicity (Kish, 2008; Cruickshank and Dyer, 
2009).  
Unlike opioid or cocaine precursors, which can be grown only in regions with suitable 
climate and soil, amphetamine-group substances can be manufactured anywhere 
with access to the appropriate ingredients. The most common ingredients for 
methamphetamine production include ephedrine or pseudoephedrine (UNODC, 
2009). Therefore, either ph nylpropanolamine or phenylacetic acid can be used to 
synthesise amphetamine. The wide availability of these relatively inexpensive over-
the-counter ingredients, coupled with the simple manufacturing process in 
clandestine laboratories, has probably contributed to the escalation of 
methamphetamine use worldwide. 
2.1.2 Epidemiology of Methamphetamine Use 
A growing area of concern has been the increasing trends of methamphetamine use 
globally. The 2009 World Drug Report suggests that the global prevalence of 















to 51 million individuals (1.2% of the global population aged 15-64 years) have used 
Methamphetamine at least once in the past 12 months (UNODC, 2009). Also, 
epidemiological data from several countries, including regions of East Asia and 
Pacific region (Farrell et al, 2002; UNODC, 2005), United States of America (Roehr, 
2005), and South Africa (Parry et al, 2004) indicate that methamphetamine 
production, trafficking, and use are steadily increasing.   
Methamphetamine abuse is a major problem in the Western Cape Province of South 
Africa, particularly the Cape Flats area in Cape Town (SACENDU, 2010). The 
annual prevalence of use among those aged 15–64 years was 0.6% in 2002 
(UNODC, 2004). In the same year, the treatment for methamphetamine abuse in 
Western Cape accounted for less than 1 percent of all substance-related treatments. 
However by 2004, this had increased to 15 percent. A year later it was 30 percent, 
peaking at 41 percent in the first half of 2007 (Plüddemann et al, 2008b). A more 
recent study on drug abuse found that methamphetamine was the primary or 
secondary drug abused by 36 percent of all treatment-seeking patients and by 73 
percent of patients younger than 20 years in Cape Town (Plüddemann et al, 2009; 
Plüddemann et al, 2008b).Thus, Cape Town is one of the cities with the sharpest 
increase in methamphetamine use in South Africa.  
The white, odourless, bitter-tasting crystalline powder that comprises 
methamphetamine can be purchased at a relatively low cost (R15-R30 per ‘straw’) 
(Plüddermann et al, 2008a). The drug can be smoked, snorted, orally ingested or 
injected intravenously. In Cape Town, methamphetamine is smoked mainly in 
crystalline form and referred to as ‘Tik’, due to the sound it makes when heated (a 















is especially potent and more likely to result in dependence than other forms of 
methamphetamine use (Topp et al, 2002). 
2.1.3 Public health effects of Methamphetamine abuse  
Methamphetamine abuse and its consequences have emerged as some of the most 
serious public health problems worldwide (SAMHSA, 2006). Its use is linked to the 
spread of HIV (Human Immunodeficiency Virus) and other sexually transmitted 
diseases, acute and chronic psychosis, road traffic accidents, violence, and family 
and social disruptions (Lee et al, 2007). In Cape Town, for example, students who 
use methamphetamine had an increased risk of contracting sexually transmitted 
infections (Plüddemann et al, 2008c), mental health problems and higher levels of 
aggressive behaviour (Plüddemann et al, 2010). 
The public health consequences of methamphetamine abuse may be due to the 
physical and psychiatric effects of the drug. Methamphetamine abuse produces 
heightened libido, increased energy and impaired impulse control which can make 
individuals engage in sexual behaviours that carry risks for transmission of infectious 
diseases (Roll et al, 2009). Also, methamphetamine-associated feelings of enhanced 
well-being, impairments in cognition and impulse control can contribute to the 
occurrence of personal and vehicular accidents, leading to care-seeking at 
emergency departments (Roll et al, 2009). In addition, violent behaviours could 
emanate from the increased aggression and mental health problems experienced by 
this group of individuals. 
Other health-related physical consequences of methamphetamine abuse include: 
seizures, cerebrovascular haemorrhage or spasm, memory loss, cardiomyopathy, 















2.1.4 Burden on Mental Health System 
Apart from physical health problems, methamphetamine use is associated with a 
range of psychiatric manifestations. Compared to other stimulants like cocaine, 
methamphetamine users in the United States are more likely to have a psychiatric 
diagnosis (Copeland and Sorenson, 2001). 
Also, a recent American study of methamphetamine-related emergency room visits 
showed that mental health problems were the most common presentations 
associated with methamphetamine use (Hendrickson et al, 2008). These psychiatric 
symptoms can cause considerable morbidity and stretch resources of mental health 
facilities. For example, the demand and need for psychiatric intervention related to 
methamphetamine use was reported to be high in Cape Town (Plüddemann et al, 
2009). Methamphetamine was found to be the most common primary substance of 
abuse in 59% of psychiatric admissions. This methamphetamine-related demand for 
mental health services in Cape Town may be far greater than can be measured by 
psychiatric admissions. Also, this may pose major challenges on provision of training 
and support to all health services dealing with these patients. 
 
2.2 METHAMPHETAMINE USE AND PSYCHIATRIC CO-MORBIDITY: 
2.2.1 Pattern of Psychiatric Co-morbidity 
The most common psychiatric symptoms experienced by methamphetamine users 
include psychoses, depression and anxiety (Glasner-Edwards et al, 2010; Zweben et 
al, 2004). The severity of these symptoms may be related to the quantity and/or 
frequency of use, the route of administration, and individual differences in sensitivity 















Methamphetamine-induced psychotic symptoms, which may mimic those of 
schizophrenia, include paranoid ideation, delusions, as well as auditory and visual 
hallucinations. Psychotic symptoms occur transiently in a substantial proportion of 
methamphetamine users (McKetin et al, 2006) and, along with other psychiatric 
symptoms, typically subside within a week of abstinence (Newton et al, 2004). 
However, in a subset of users, psychosis may persist for several months or longer 
after sustained abstinence (Iwanami et al, 1994; Ujike and Sato, 2004).  
As in the case of alcohol and cocaine, a review of articles did reveal that 
methamphetamine can cause depressive symptoms in active users, which may remit 
spontaneously early in abstinence or have a prolonged course (Meredith et al., 
2005). Among a sample of methamphetamine users drawn from three sites in the 
United States, Glasner-Edwards et al (2009) found that depressive symptoms 
declined during the course of treatment in the overall sample, with greater reductions 
among those who abstained from methamphetamine during treatment relative to 
those who used. Abstainers shifted from clinically relevant symptom levels at 
baseline to the normal or minimal symptom range at discharge. 
Similar to other psychoactive stimulants, methamphetamine can trigger manic 
episode in patients with pre-existing diagnosis or a predisposition to bipolar disorders 
(Chen et al, 2003).  
Anxiety disorders have been reported among methamphetamine users (Zweben et 
al, 2004). Anxiety symptoms commonly emerge both during methamphetamine 
intoxication (Cruickshank and Dyer, 2009) and withdrawal (McGregor et al, 2005), 
although the extent to which such symptoms persist following cessation of 















symptomatology in methamphetamine users may be explained, in part, by activation 
of the sympathetic nervous system via alpha receptor stimulation, a putative 
methamphetamine-specific mechanism (Cruickshank and Dyer, 2009). 
When intoxicated, users may become agitated or violent (Richards et al, 1999; 
Zweben et al, 2004) and nearly one-third of treatment-seeking users have reported a 
history of suicide attempts (Glasner-Edwards et al, 2008; Zweben et al, 2004). 
2.2.2 Prevalence of Psychiatric Co-morbidity 
Although psychiatric symptoms are frequently observed in methamphetamine users, 
little is known about the prevalence of psychiatric disorders among 
methamphetamine-dependent individuals in low and middle income countries. 
Syndromes such as methamphetamine psychosis (Sato, 1992) have received 
descriptive attention over the past decade, but the prevalence of this and other more 
frequently occurring disorders or sequelae (e.g. depression, anxiety disorder) in 
methamphetamine users have not often been rigorously studied.  
A recent study of methamphetamine dependent subjects in the U.S found that 48.1% 
of the sample met criteria for a current or past psychiatric disorder (Glasner-Edwards 
et al, 2010). This rate was largely accounted for by mood disorders, anxiety 
disorders and antisocial personality. Although the study had a large sample size of 
526, limitations include the use of MINI (Mini-International Neuropsychiatric 
Interview) in making definitive psychiatric diagnoses, as well as the exclusion of 
patients with psychiatric disorders severe enough to warrant primary treatment. The 
MINI does not distinguish substance-induced from primary psychiatric syndromes 
neither does it determine order of onset of substance use relative to psychiatric 















needing primary treatment could have resulted in underestimation of the prevalence 
rates of psychiatric diagnoses. 
Among methamphetamine dependent individuals, a subset develops severe 
recurrent psychotic symptoms, commonly termed ‘Methamphetamine psychosis’. 
These symptoms are often associated with high levels of psychiatric hospitalisation 
and serious social dysfunction (Chen et al., 2003). Several studies have examined 
the prevalence of methamphetamine psychosis and one study reported a lifetime 
prevalence of 27% (all substance-induced) based on the SCID (Shoptaw et al., 
2003). Another study reported that 23% of their sample had symptoms of psychosis 
in the previous year, as measured by the Brief Psychiatric Rating Scale (McKetin et 
al., 2006).When subjects who had a history of non–drug-induced psychotic disorder 
were excluded, the past year prevalence was 18%. A more recent study however 
reported that 12.7% of their sample met criteria for a lifetime psychotic disorder 
(Glasner-Edwards et al., 2010). 
Depressive disorders are more prevalent among methamphetamine users than in 
the general population (Glasner-Edwards et al, 2009). In a comparison of 46 
methamphetamine users with 31 non-users, trends were observed for more 
symptoms of depression in the methamphetamine users (Nakama et al, 2008). Also, 
more than half (52%) of gay or bisexual men seeking treatment for 
methamphetamine abuse or dependence had mood disorders; 41% of these met 
criteria for substance-induced mood disorders (Shoptaw et al, 2003). Similarly, a 
study of 1580 arrestees found that those with Methamphetamine dependence were 
significantly more likely than other arrestees to report histories of depressive 















the syndrome of depression; the findings remained statistically significant after 
controlling for demographic profile, HIV serostatus, and history of other substance 
dependence. Therefore, the use of methamphetamine can result in depressive 
symptoms not only in the aftermath of the use episode, but months thereafter 
(Zweben et al, 2004). It is however not clear if these depressive symptoms are part 
of ‘Methamphetamine Withdrawal Syndrome’ or constitute an independent entity. 
Prevalence rates of anxiety disorders have been reported among methamphetamine 
using populations. These rates vary between studies. Hall et al (1996) found that 
over three quarters of amphetamine users reported anxiety symptoms. On the other 
hand, nearly 40% of treatment-seeking methamphetamine users in another study 
had history of anxiety disorders (McKetin et al, 2008). In a recent research, Salo et al 
(2010) reported 24.3% lifetime prevalence rate of anxiety disorders and 3.7% for 
methamphetamine-induced anxiety disorders among individuals dependent on 
methamphetamine. Similar to this, a 3-year follow-up study of methamphetamine 
dependent adults found that 26.2% of them met criteria for a current or past anxiety 
disorder (Glasner-Edwards et al, 2010b). Commonly reported anxiety disorders were 
generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, 
panic disorder and agoraphobia. Those with anxiety disorders poorly adhered to 
treatment and had a higher frequency of methamphetamine use during the follow-up 
period (Glasner-Edwards et al, 2010b). 
Although there is a consensus amongst studies about the presence of psychiatric 
disorders in Methamphetamine users, some of the studies that reported on 
prevalence rates have key limitations. Nakama et al (2008) had a small sample size 















of education; evaluated based on self-reports. Low socio-economic status 
independent of substance abuse may be related to greater psychiatric symptoms. 
Also, substance users can be poor historians thereby bringing to question the validity 
of their psychiatric diagnoses.  
The findings of another study by Semple et al (2007) might be difficult to generalise 
to all methamphetamine users as it focused only on females and lacked structured 
diagnostic instrument. Shoptaw et al (2003) on the other hand made use of the 
SCID, a structured diagnostic instrument but the study was carried out amongst gay 
and bisexual men.  
A more robust, large sample sized (n = 1580) study of psychiatric morbidity amongst 
methamphetamine dependent individuals of both genders was carried out by 
Kalechstein et al (2000) in California. The sample was a forensic one consisting of 
arrestees in City and County jails who agreed to participate in the study. Also, 
premorbid psychopathology was not assessed, making it difficult to distinguish 
between methamphetamine-induced psychiatric symptoms and independent 
psychiatric symptoms. More also, standardised measures like the SCID was not 
used to assess for the presence of psychiatric disorders.  
Despite the increasing trends of methamphetamine use in some parts of South 
Africa, there is paucity of research on prevalence of psychiatric co-morbidity among 
methamphetamine users in this part of the world. In fact, none of the studies 
















2.2.3 Psychiatric Co-morbidity and Treatment outcome of Substance use 
disorder 
Psychiatric disorders may lead to drug dependence (Swadi, 1999). Conversely, the 
drug use may also result in psychiatric symptoms (Miller and Fine, 1997). When co-
occurring psychiatric disorders are present, they may adversely affect the response 
to treatment of substance use disorders (Carroll et al, 1993). 
A recent study of methamphetamine-dependent adults 3 years after treatment 
revealed that the presence of psychiatric co-morbidity was associated with poorer 
treatment and functional outcomes (Glasner-Edwards et al, 2010). Those with Axis I 
psychiatric disorders had increased methamphetamine use and greater functional 
impairment over time relative to those without psychiatric disorders.  
Substance-dependent individuals with a co-morbid psychiatric disorder are more 
likely to relapse than individuals without a co-morbid psychiatric disorder (Brady et al, 
1990; Carroll et al, 1993).The exact mechanism through which co-morbid psychiatric 
disorder affect treatment outcome is unclear. One potential mechanism is Readiness 
for Change. 
 
2.3 READINESS FOR CHANGE: 
Motivation or Readiness for Change refers to a central mechanism or constellation 
of mechanisms that lie at the heart of why and how people change addictive and 
health behaviours (Miller, 2006). Motivation is a critical determinant of an individual's 
performance and may influence the outcome of behaviour (Bandura, 1986; Miller, 
1985). Although there are different theories about motivation (Miller, 1985; Miller, 















his or her goals and intentions, the need to take responsibility and make a 
commitment to change, as well as sustaining the behaviour change (DiClemente et 
al., 2004; Miller and Rollnick, 2002). 
These multiple motivational tasks and the broader phenomenon of intentional 
behaviour change have been described as the Stages of Change in the Trans- 
Theoretical Model (TTM) of behaviour change developed by Prochaska and 
DiClemente (1984).   
The trans-theoretical model depicts a sequence of stages through which people 
progress as they initiate and maintain behaviour change. The first of these is termed 
precontemplation, a state of unawareness of a problem or need for change. As 
problem awareness increases, the person enters a state of ambivalence or 
contemplation, in which pros and cons are weighed (Miller and Rollnick, 2002). 
Over time, the decisional balance may tip in favour of change, as adverse 
consequences (cons) outweigh the perceived advantages of status quo (pros), a 
process paralleling the idea of bottoming out. In their original model, Prochaska and 
DiClemente (1984) termed this point of shifting balance the determination stage but 
subsequently deleted this stage and later reinstated it, reconceptualising this 
transitional period as a preparation phase (Prochaska and DiClemente, 1992; 
Prochaska et al, 1992). Next the person moves into an action stage in which efforts 
are made to change behaviour. If these initial efforts are successful, the 
maintenance stage involves relapse prevention (DiClemente et al., 2004), taking 
steps to protect against reversion to the prior behaviour pattern. Given that 
behaviour change is not perfectly maintained on the first try in most cases, a relapse 















again through contemplation, determination-preparation, action, and maintenance in 
order to achieve lasting behaviour change. 
Stage-specific tasks need to be accomplished well enough to support forward 
movement toward the successful establishment of new behaviour, and often, 
individuals need to recycle through the stages multiple times to accomplish this 
(DiClemente, 2003; DiClemente, 2005). The tasks of each of the stages play an 
important role in what has been described as readiness to change behaviour. 
2.3.1 Drug use and Readiness for Change  
The role of motivation in the modification of addictive behaviours and the eventual 
recovery process has been studied. Findings from the studies demonstrate a positive 
correlation between motivation for change and substance abuse treatment outcomes 
(De Leon et al., 1994; Simpson and Joe, 1993). Motivation to change substance 
abuse behaviour has been associated with treatment engagement, quit attempts, 
treatment retention, sustained abstinence, and better treatment outcomes among 
individuals diagnosed with alcohol and cocaine dependence (Joe et al., 1998; 
Pantalon et al., 2002 and Stotts et al., 2001). 
Although readiness for change has been widely reported as predictive of treatment 
outcome of alcohol and drug dependence, Project MATCH (1998) in the United 
States did not find this association among in-patient alcohol dependent samples. In 
Project MATCH, baseline readiness scores were more predictive when assessed in 
the outpatient arm compared to the inpatient arm of the trial. It did appear that the 
evaluation of motivation and stage of change was more difficult to obtain when 
patients were in protected environments, where abstinence was supported by the 















Nonetheless, Motivational enhancement interventions have often produced improved 
outcomes compared with control conditions in a range of alcohol- and drug-abusing 
patients (Miller and Rollnick, 2002; Stotts et al., 2001).  Therefore, it may be possible 
for a physician to increase motivation (e.g., through Motivational Enhancement 
Therapy) and thus help a patient move from an early stage of change (e.g. 
contemplation) to a more active and healthy stage (e.g. action).  
Research has shown that several factors predict the stage of change and readiness 
for change in substance-using population. DiClemente et al (2009) reported that age 
and gender predicted readiness for change among alcohol dependent people. Other 
factors, like longer past abstinence and presence of psychiatric co-morbidity were 
reported as predictors of readiness to quit tobacco smoking (Martin et al, 2006; 
Unrod et al, 2004). 
There are many ways to evaluate readiness for change. These range from a 
readiness ruler (e.g., on a scale of 1 to 10, how ready are you to change this 
behaviour [quit smoking, stop using illegal drugs]?), to more complex multiple-
subscale measures (DiClemente et al., 2004).  These multiple-subscale measures, 
like the University of Rhode Island Change Assessment (URICA) and the Stage of 
Change, Readiness, and Treatment Eagerness Scale (SOCRATES), have been 
used most often with alcohol- and drug-abusing individuals because they are 
sensitive to various types of attitudes and intentions and less vulnerable to social 
desirability or simple denial of a problem. However, these types of measures rely 
















2.3. Readiness for Change and Psychiatric Co-morbidity  
Readiness for change in a drug dependent patient might be affected by the presence 
of co-morbid psychiatric disorder. In a study of nicotine dependent individuals with 
co-morbid psychiatric disorder, for example, it was found that smokers with dual 
diagnoses (i.e., substance abuse and other psychiatric diagnoses) differ from 
smokers without psychiatric co-morbidity in their level of knowledge of the hazards of 
smoking and the benefits of quitting, and their reported readiness to change 
(Carosella et al, 1999). However, a recent critical review of the literature showed that 
psychiatric co-morbidity is not a consistent predictor of motivation to quit smoking 
(Heffner et al, 2007).   
Among Methamphetamine-dependent patients, there is a paucity of data on the 
relationship between readiness for change and presence of co-morbid psychiatric 
disorders. Is readiness for change affected by some psychiatric conditions?  
 
2.4 RELEVANCE OF THE STUDY: 
Little is known about the pattern and prevalence of psychiatric co-morbidity among 
methamphetamine using population in Cape Town. This is in spite of reported 
increase in methamphetamine-related psychiatric hospitalisations in the Town. An 
understanding of the relationship between this psychiatric morbidity and important 
predictors of treatment outcome like Readiness for change is needed for adequate 
treatment of this category of people. 
This study therefore seeks to fill the knowledge gap in a developing country like 















findings from the study will be useful in answering the question of the magnitude of 
psychiatric issues faced by individuals dependent on methamphetamine. 
By addressing the relationship between psychiatric co-morbidity and readiness for 






























AIMS AND OBJECTIVES 
3.1 GENERAL AIM: 
To determine the relationship between psychiatric co-morbidity and readiness for 
change (motivation) among individuals dependent on methamphetamine in Cape 
Town.  
 
3.2 SPECIFIC OBJECTIVES: 
1. To find the prevalence and patterns of psychiatric disorders among the study 
population. 

























4.1 Study Design: 
This is a descriptive cross-sectional study carried out over a period of four months.  
 
4.2 Study Locations:  
The study was conducted at the Methamphetamine Clinic of J- block Psychiatry 
outpatient unit in Groote Schuur Hospital and two drug rehabilitatio  centres in Cape 
Town. Referrals came from a third drug rehabilitation centre to the 
methamphetamine clinic. This clinic provides follow-up psychiatric services for 
patients with methamphetamine-related disorders.  
 
4.3 Study Population: 
The study sample was drawn from among all the clients attending two out-patient 
and one in-patient drug rehabilitation centres in Cape Town. 
 
4.4 Sample Selection: 
a. Inclusion criteria:  
i) Participants aged 18 years and above. 
ii) Diagnosis of Methamphetamine dependence on the Mini-International 
Neuropsychiatric Interview (MINI). 
b. Exclusion criteria: 















ii) Self-reported diagnoses of chronic medical disorders (such as cardiac, 
renal, hepatic, cerebrovascular, pulmonary or infectious diseases including 
HIV).  
iii) Inability to give informed consent. 
 
4.5 Sample size: 
A total of 60 consecutive participants who consented were recruited for this study. 
 
4.6 Recruitment and Enrolment:  
Participants were recruited from two out-patient and one in-patient drug rehabilitation 
centres in Cape Town. The researcher paid initial visits to these centres and held 
meetings with the counsellors. These meetings were used to disseminate 
information about the study, explain inclusion and exclusion criteria and secure the 
co-operation of the counsellors. Handbills and posters advertising the most important 
features of the study were placed in these centres. Each centre was given a 
notebook which was used by interested clients to enter their names and contact 
details. 
Follow-up visits were made to these centres. During such visits, interested clients 
were seen individually to explain more about the study, screen for methamphetamine 
dependence; rule out exclusion criteria and obtain written informed consent. 
Clients eligible for the study and willing to come to Groote Schuur hospital on their 
own were given referral to the Methamphetamine Clinic with an appointment date for 
evaluation. For those with transportation problems, an appointment was set up with 















respective centres. These appointments did not interfere with the clients’ therapeutic 
sessions.  
Volunteers who transported themselves to the Methamphetamine clinic were given 
food vouchers each at the end of the evaluation. All the participants from the in-
patient drug rehab had their evaluations at the rehabilitation centre.  
   
4.7 Instruments: 
1. Mini-International Neuropsychiatric Interview (MINI): The MINI is a short 
diagnostic structured interview, developed by psychiatrists for DSM-IV and ICD-10 
psychiatric disorders. It has similar reliability and validity properties as the Structured 
Clinical Interview for DSM‐III‐R patient (SCID-P) and the Composite International 
Diagnostic Interview (CIDI) (Sheehan et al, 1997). Among patients of psychiatric 
facilities in Florida and Paris, previously reported sensitivity was 0.70; specificities, 
negative predictive values and efficiency scores were 0.85 or higher across all the 
diagnoses (Sheehan et al, 1997).   
With an administration time of approximately 15 minutes, it was designed to meet the 
need for a short but accurate structured psychiatric interview for multicenter clinical 
trials and epidemiology studies and to be used as a first step in outcome tracking in 
non-research clinical settings.  
Modules I and J of the sixth version of the MINI which evaluates Alcohol dependence 
and Substance dependence respectively were used to screen volunteers for 















2. Socio-demographic Questionnaire: This was designed by the researcher to 
gather important socio-demographic characteristics of the participants; 
methamphetamine use history, previous psychiatric history and leisure time 
activities. It is made up of four sections.  
The terms ‘black’, ‘white’ and ‘coloured’ in Question 3 of this Questionnaire were 
used given their historical significance in the South African context. Although they do 
not signify inherent characteristics, these demographic markers continue to predict 
local health disparities. The terms refer to people of African, European and mixed 
(African, European and/or Asian) ancestry respectively. 
3. Severity of Dependence Scale (SDS): The Severity of Dependence Scale (SDS) 
is a short, five-item scale which can be used to measure degree of dependence 
upon different drugs (Gossop et al, 1995; Gossop et al, 1997). Each of the items is 
scored on a four-point scale (0, never/almost never; 1, sometimes; 2, often; 3, 
always/nearly always for items 1-4: and 0, not difficult; 1, quite difficult; 2, very 
difficult; 3, impossible for item 5). A total SDS score can be obtained by addition of 
scores for all items with higher total scores indicating higher levels of dependence. 
Among samples of drug users in London and Sydney, the test-retest reliability for the 
total SDS scores (an aggregation of the five-item scores) was found to be 0.89 
(Gossop et al, 1995). This indicates that the SDS has good retest reliability and, in 
this respect, provides a reliable measure of dependence. 
The SDS is easy to understand. It can be completed by most drug users in less than 
a minute, and it has proved to be a useful research tool. Though yet to be validated 















4. Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I): The 
SCID-  (First et al, 2002) is a semi-structured interview for making the major DSM-IV 
Axis I diagnoses. It has two versions: Clinician and Research versions. The research 
version of the SCID is much longer than the Clinician Version because it contains 
more disorders, subtypes, severity and course specifiers, as well as provisions for 
coding the specific details of past mood episodes. It is designed to include most of 
the information that is diagnostically useful to researchers. Two standard editions of 
the research version of the SCID-I are available: the Patient Edition (SCID-I/P) and 
the Non-patient Edition (SCID-I/NP). While The SCID-Patient Edition is designed for 
use with subjects who are identified as psychiatric patients, the SCID-I/NP (Non-
patient Edition) is for use in studies in which the subjects are not identified as 
psychiatric patients (e.g. community surveys, family studies, research in primary 
care). For settings in which psychotic disorders are expected to be rare (e.g. an 
outpatient anxiety clinic) or for studies in which patients with psychotic disorders are 
being screened out, an abridged edition of the Patient Edition (SCID-I/P W/ 
PSYCHOTIC SCREEN) is available.  
In the current study, the SCID-I served as the primary means of making the 
diagnoses of Psychiatric disorders. This is made up of a Summary Score Sheet, an 
Overview and modules A to J. These modules cover Mood Episodes, Psychotic and 
Associated Symptoms, Psychotic Disorders, Mood Disorders, Substance Use 
Disorders, Anxiety Disorders, Somatoform Disorders, Eating Disorders, Adjustment 
















5. Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES) 
The SOCRATES (Miller and Tonigan, 1996) is a self-report Readiness to change 
assessment instrument created specifically for alcohol and substance use. There are 
two versions of the scale:  an alcohol version (SOCRATES 8A) and a drug version 
(SOCRATES 8D). The versions are identical except that words such as “drinking” on 
the alcohol version of the scale are replaced with “drug use” on the drug use version. 
The present study used SOCRATES 8D, which is designed specifically for drug-
using populations. It consists of 19 items, each of which is scored on a five-point 
Likert scale (e.g., 1 = No! Strongly Disagree; 5 = Yes! Strongly Agree). The item 
scores yield three subscales: Recognition, Taking Steps, and Ambivalence.  
Recognition comprises seven items (score range: 7–35) regarding acknowledgement 
of a drug-related problem and desire for change. Ambivalence comprises four items 
(score range: 4–20) and measures perceived control over drug use and drug 
problems. Taking steps comprises eight items (score range: 8–40) which measure 
the extent to which individuals are making positive efforts to change their drug-using 
behaviour. In the current study, the stage of change by each respondent was 
determined by using the subscale with the highest score. 
Psychometric analysis of the SOCRATES within a group of substance dependent 
military service members in the United States showed that the instrument has good 
internal consistency (alphas were: 0.93 for Recognition, 0.84 for Taking Steps, and 


















4.8 Research Procedures:  
This study consisted of two stages. The first stage involved the screening of 
volunteers with the I and J modules of the MINI to ascertain their eligibility for the 
study. This screening was done as one-on-one brief clinical interview by the 
researcher and lasted for 10 minutes on the average. Volunteers who met the 
inclusion criteria were taken through the process of informed consent and given 
appointment for the second stage of the study within one week of the initial 
screening. 
During the second stage, all the study instruments (Socio-demographic 
Questionnaire, SDS, SCID-I and SOCRATES 8D) were administered on a single 
day. Participants self-administered SDS and SOCRATES 8D while the researcher 
administered the Socio-demographic Questionnaire and SCID to them. All study 
instruments were administered in English language. 
 
4.9 Beneficence and Maleficence:  
This research was part of a bigger study which received ethical approval from the 
Health Sciences Faculty Research Ethics Committee (HREC REF: 340/2009). The 
study was conducted in accordance with the guidelines of The Declaration of 
Helsinki (WMA, 2008) and the South African Medical Research Council on the 
ethical conduct of research in humans (2008).These guidelines were strictly adhered 
to during and after the study. 
Written informed consent was obtained from all participants. The volunteers 
participated willingly as they were made to understand that they could withdraw from 















Data collection, analysis and presentation were done without compromising 
confidentiality. 
Subjects found to have psychiatric co-morbidity were given the option of continuing 
psychiatric care at the methamphetamine clinic or referred to an appropriate 
psychiatric facility. 
 
4.10 Data Analysis: 
The variables for analysis were coded for easy data entry. Data entry and analysis 
were done using the 19th version of the Statistical Package for Social Sciences 
(SPSS, 2011). A frequency distribution of all variables was carried out as part of data 
exploration and cleaning. 
Assumption of normality was tested using the Shapiro-Wilk’s test. Descriptive 
statistics such as means, medians, inter-quartile range (IQR), frequencies and 
proportions were used to summarize variables.  
Independent variables include socio-demographic and drug use parameters; the 
main outcome measures (dependent variables) were psychiatric co-morbidity and 
readiness for change. 
The quantity of ‘Tik’ was converted to grams. The conversion was done through a 
focus-group discussion with respondents who had sold methamphetamine before 
entering treatment (e.g five R30 ‘straw’/’pack’ of ‘Tik’ equals one gram). 
Readiness for change was recorded in two forms: ‘Stage of change’ and ‘Level of 
Readiness for change’. The stage of change for each respondent was determined 















These stages of change (i.e Recognition, Ambivalence and Taking steps) were used 
to identify the level of Readiness for change. There were 2 categories: “High 
readiness for change” and “Low readiness for change”. The “High readiness for 
change” category is made up of respondents at the stage of ‘Taking steps’. All the 
respondents at the stages of ‘Recognition’ and ‘Ambivalence’ were grouped together 
into the “Low readiness for change” category. 
Relationship between each of the SOCRATES stages of change (Recognition, 
Ambivalence and Taking Steps) and independent variables were explored using T-
test. Analysis of Variance (ANOVA) was used to compare the mean scores of 
variables with more than two groups. Where significant difference was detected by 
ANOVA, this was subjected to Post hoc test to identify between group differences. 
Also, the mean score of each stage of change was compared between respondents 
with psychiatric co-morbidity and those without psychiatric co-morbidity.  
In addition, bivariate associations between outcomes psychiatric co-morbididty and 
categorical variables were tested using the Chi-square (X2) test. Fisher’s exact test 
was used whenever the expected count was less than five in more than 25% of the 
cells in cross-tabulations. Factors found to be significant in the unadjusted 
associations [Chi-square or Fisher’s] were entered into a multiple logistic regression 
[multivariate] analysis to identify factors independently associated with psychiatric 
co-morbidity.  
Spearman’s correlation coefficient test was used as a measure of correlation 
















A confidence interval of 95% which allows for 5% sampling error, at significance 







































5.1 SOCIO-DEMOGRAPHIC CHARACTERISTICS OF RESPONDENTS 
Table 1 shows the Social-demographic characteristics of the respondents. 
Nearly all the respondents (96.7%) were of the ‘coloured’ race and unemployed 
(90.0%). Most left school in grades 7-11 (71.6%); not completing the matric class. 
There were more males than females (71.7% vs 28.3%). The age range of the 
respondents was 18 to 44 years with a median of 26.00 (Inter-quartile range: 22-30). 
The mean score of the Severity of dependence scale was 10.08 (SD:2.95). 
 
Table 1:  Socio-demographic Characteristics 
 














































































Highest Education  
≤ Grade 6 




































5.2 DRUG USE, METHAMPHETAMINE TREATMENT AND ABSTINENCE 
As shown in Tables 2-5, Cannabis was the earliest drug of abuse in two-thirds 
(66.7%) of the respondents. The median age of first ever drug use was 16 years 
(IQR: 13 -18). About four out of every five respondents (81.7%) used one or more 
grams of methamphetamine per week. The mean duration of methamphetamine use 
was 6.58 years (SD=2.73). About a quarter of respondents (26.7%) had been 
previously treated for methamphetamine dependence. Only 40.0% had maintained 
























Table 2: General drug use  
 
Variables Frequency (n=60) Percentage (%) 






































Table 3: Methamphetamine use 
Variables Frequency (n=60) Percentage (%) 
























Pattern of use 
Twice a week/Weekends 




























Table 4: Methamphetamine Treatment and Abstinence 




























































Both in and out-patient 
































































Table 5: Social Activities 
Variables Frequency (n=60) Percentage (%) 
Leisure activities 
Drug related 

























5.3 PAST PSYCHIATRIC HISTORY AND CURRENT PSYCHIATRIC 
COMORBIDITY 
Of the eleven respondents who had a previous personal history of psychiatric 
disorder, more than half (63.6%) of these were temporally later than 
methamphetamine use.  
Current psychiatric co-morbidity was found in 38.3% of all respondents. The most 
common were mood disorders (18.3%), psychotic disorders (13.3%) and anxiety 
disorders (6.7%).  Bipolar disorder Not Otherwise Specified (Intermittent hypomanic 
episodes) was the most common mood disorder while Paranoid schizophrenia 
























Table 6: Previous Psychiatric History 






















Onset of Personal 
History 
Before Meth use 
After Meth use 
 














Table 7: Current Psychiatric Co-morbidity 











Number of Psychiatric 
disorders 
One 
Two or more 
 












































Bipolar NOS (Mixed 
episode) 
Bipolar NOS (Intermittent 
Hypomanic episodes) 














Panic disorder (with 
Agoraphobia) 
Panic disorder (without 
Agoraphobia) 
Specific Phobia (Heights) 



























































n 3 = Respondents with psychiatric co-morbidity. 
Bipolar NOS = Bipolar disorder Not otherwise specified 
SIMD = Substance Induced mood disorder 
Psychotic disorder NOS = Psychotic disorder Not otherwise specified 















5.4 CURRENT PSYCHIATRIC CO-MORBIDITY AND READINESS FOR 
CHANGE 
Sixty percent of the respondents were at the stage of Taking Steps. Respondents 
with psychiatric co-morbidity were no less likely to be at this stage of change. 
However, respondents with psychiatric co-morbidity had significantly lower scores on 
the dimension of ‘Recognition’ compared to those without psychiatric co-morbidity   
(p=0.01). The difference in level of change with respect to current psychiatric co- 
morbidity was not statistically significant (p>0.05). (Tables 8, 9A and 9B)  
 
 
Table 8: Readiness for change 
Variables Frequency (n=60) Percentage (%) 






















































Table 9A: Psychiatric Co-morbidity and Readiness for change  
 
Variables No Psyc. comorbid 
(n = 37) 
 Psyc.comorbid 


















2                          5.4 
13                      35.1 




0                       0.0 
9                     39.1 
14                   60.9 











15                      40.5 




9                     39.1 











f= Fisher’s exact test 
X2 = Chi-square.   




Table 9B: Psychiatric Co-morbidity and Stage of Readiness 
 
Variables No Psyc. comorbid 
(n = 37) 
 Psyc.comorbid 















































































5.5 FACTORS INDEPENDENTLY ASSOCIATED WITH CURRENT 
PSYCHIATRIC CO-MORBIDITY 
Gender, family history of psychiatric disorder and previous personal history of 
psychiatric disorder had a significant association with current psychiatric co-morbidity 
(p<0.05) (Tables 10-14). However, after controlling for the effects of the other 
variables, the factors independently associated with current psychiatric morbidity 
include gender, previous personal history of psychiatric disorder and age. Being a 
male was a risk factor for psychiatric co-morbidity (odds ratio = 7.91, CI = 1.09-
57.01, p = 0.04). Also, having previous psychiatric history increased the risk of 
current psychiatric co-morbidity among the respondents (odds ratio = 18.50, CI = 
2.64-129.87, p = 0.003). The risk of psychiatric co-morbidity increases as age 



























Table 10:  Psychiatric Co-morbidity and Socio-demographic 
Characteristics 
 
Variables No Psyc. comorbid 
(n = 37) 
 Psyc.comorbid 












14                      37.8 
23                      62.2 
 
3                    13.0 












10                      27.0 
20                      54.1 
7                        18.9 
 
10                  43.5 
13                  56.5 











0                         0.0 
37                    100.0     
 
2                     8.7 












1                          2.7 
23                      62.2 
13                      35.1 
 
2                      8.7 
17                  73.9 













25                      67.6 
12                      32.4 
 
20                  87.0 







Highest Education  
Below Matric 
Matric and above 
                        
27                      73.0 
10                      27.0 
 
17                   73.9 
6                     36.1 













35                     94.6 
2                         5.4 
 
 
19                  82.6 


































Table 11:  Psychiatric Co-morbidity and Methamphetamine use 
 
Variables No Psyc. comorbid 
(n = 37) 
 Psyc.comorbid 







Frequency        % Frequency         % 







3                          8.1 
34                      91.9 
 
 
5                    21.7 















5                        13.5 
32                      86.5 
                         
 
 
6                    26.1 










Pattern of use 
Twice a week or  
Weekends 




7                        18.9 
 
11                      29.7 
19                      51.4     
 
2                      8.7 
 
6                   26.1 








































Table 12:  Psychiatric Co-morbidity and Methamphetamine 
Treatment/Abstinence 
Variables No Psyc. comorbid 
(n = 37) 
 Psyc.comorbid 












17                      45.9 
20                      54.1 
 
12                   52.2 














2                          5.4 
25                      67.6 
10                      27.0 
 
 
4                     17.4 
10                   43.5 











34                      91.9 
3                          8.1     
 
20                   87.0 











28                      75.7 
9                        24.3 
 
 
16                   69.6 


















3                          8.2 
17                      45.9 
17                      45.9 
 
 
1                       4.3 
15                   65.2                   

































Table 13:  Psychiatric co-morbidity and Social Activities 
 
Variables No Psyc. comorbid 
(n = 37) 
 Psyc.comorbid 







Frequency        % Frequency         % 
Leisure activities 
Drug related 
Non Drug related 
 
 
8                        21.6 
29                      78.4 
 
7                    30.4 












6                        16.2 
31                      83.8 
 
5                    21.7 


















Table 14: Psychiatric Co-morbidity (Current) and Psychiatric History 
 
Variables No Psyc. comorbid 
(n = 37) 
 Psyc.comorbid 













36                      97.3 
1                          2.7 
 
17                   73.9 













35                      94.6 
2                          5.4 
 
 
14                   60.9 































Table 15: Adjusted logistic regression analyses of variables 
associated with Psychiatric Co-morbidity 
Variables 
Beta Wald P-value. 
Odds 
ratio 



























-0.176 4.544 0.033* 0.839 0.713 0.986 










































































Constant 2.884 1.335 0.248 17.892   
*= p-value is significant 
Age is modelled in logistic regression as it is an important health variable with a 
























5.6 FACTORS ASSOCIATED WITH READINESS FOR CHANGE 
5.6.1 The Stage of Recognition 
As depicted in Table 16, females had significantly higher recognition scores 
compared to males (p = 0.04). Also, difference in mean recognition scores with 
respect to religious affiliation was statistically significant (p = 0.02). Respondents with 
religious affiliation had better recognition of the drug problem in comparison to those 
with no religious affiliation. Post hoc analysis showed that those without religious 
affiliation had significantly lower scores compared to either Christians or Muslims    
(p < 0.05).   
Another important variable found to be significantly associated with recognition is 
previous psychiatric history. Having a previous personal psychiatric history was 
associated with significantly lower recognition score (p = 0.02). (See Table 20) 
  
5.6.2 The Stage of Ambivalence 
The nature of respondents’ leisure activities was the only factor which showed 
significant association with Ambivalence to change. Table 19 showed that 
respondents with drug related leisure activities had significantly higher ambivalence 
scores than those with non-drug related activities (p = 0.002).  
 
5.6.3 The Stage of Taking steps 
As shown in Table 16, respondents with below matric educational level had 
significantly higher scores on Taking steps (p =0.02). 
Also notable is the trend for higher ‘Taking steps’ score by respondents with non-



























P value Mean 
Score 










































































































































































F= ANOVA (Analysis of Variance). 




















 Table 17: Readiness for change and Methamphetamine use 
 
Variables Recognition Ambivalence  Taking Steps 
Mean 
Score 
P value Mean 
Score 
P value Mean 
Score 
P value 






















































Pattern of use 
Twice a week or 
Weekends 
























































Table 18: Readiness for change and Methamphetamine       
Treatment/Abstinence 




P value Mean 
Score 
















































































































































Table 19: Readiness for change and Social Activities 
 





P value Mean 
Score 















































Table 20: Readiness for change and Previous Psychiatric History 
 





P value Mean 
Score 































































As shown in Tables 21 below, the quantity of methamphetamine used per week 
positively correlated with the SOCRATES’ dimensions of ‘Recognition’ (p=0.02) and 
‘Taking Steps’ (p=0.003). ‘Taking Steps’ correlated negatively with the duration of 
methamphetamine use (p=0.02) and the dimension of ‘Ambivalence’ (p=0.0001). 
Also, there was a negative correlation between ‘Ambivalence’ and duration of current 
drug treatment (p=0.01).  
These findings suggest that the more the quantity of methamphetamine used, the 
greater the recognition of the problem. Also, longer duration of methamphetamine 
use was associated with increased ambivalence towards change. This ambivalence, 
however, reduces with longer stay in treatment. 
 
Table 21:  Significant Correlates of SOCTRATES dimensions 
Test variables 
                 → 

























 Recognition  Correlation 
Coefficient 
      0.313
*
  
Sig. (2-tailed)       0.015  
N       60  
Ambivalence  Correlation 
Coefficient 
   -0.602
**
    -0.339
**
 
Sig. (2-tailed)    0.000    0.008 
N    60    60 









Sig. (2-tailed)   0.000   0.021 0.003  
N   60   60 60  
*. Correlation is significant at the 0.05 level (2-tailed).                                                   
**. Correlation is significant at the 0.01 level (2-tailed). 

















6.1 SOCIO-DEMOGRAPHIC CHARACTERISTICS 
There were significantly more males than females in this study. This is in sharp 
contrast to the findings of Zweben et al (2004) who found more females than males 
in their American cohort of methamphetamine users in treatment programs. Although 
females may be particularly vulnerable to the reinforcing effects of stimulant drugs 
such as methamphetamine (Lynch, 2006), males have exhibited significantly higher 
rates of substance use, abuse and dependence in the United States (Compton, 
2007). In Cape Town, women with Substance use disorder are more negatively 
perceived than their male counterparts (Myers et al, 2009). Previous research 
revealed that moral discourses around substance use and intoxication are 
particularly salient for women, compared to men; with female substance abuse 
generally associated with sexual availability and an inability to fulfil traditional gender 
roles (Myers et al, 2009). These representations may hinder treatment-seeking for 
women, as they may deny or hide their condition for fear of being labelled, for fear of 
having their children removed from their care, and for fear that treatment providers 
will be judgmental. Support for this explanation emerges from findings of negative 
perceptions towards women who use substances by health professionals and 
community-based organisations in South Africa (Sonja et al, 2008) 
Similar to previously observed trends in treatment settings (SACENDU, 2010), the 
majority of respondents were below the age of 35 years, single, had secondary 















respondents were of the ‘coloured’ race. This finding is consistent with prior reports 
by twenty-two specialist treatment centres in Cape Town (SACENDU, 2010). The 
high proportion of ‘coloured’ people in this study may be partly explained by the high 
concentration of ‘coloured’ people in the Western Cape Province (Small, 2008). 
However, this group of people has a long history of social deprivation, 
unemployment, poverty, alcoholism, crime and gangsterism, which may in turn lead 
to substance use (Legget, 2004). 
The characteristics of the sample in this study are a reflection of admission policies 
and the very specific populations served by the treatment centres that were used as 
sampling sites. 
6.2 METHAMPHETAMINE USE, PATTERN AND ABSTINENCE 
This study showed that teenagers are particularly vulnerable to using drugs. The 
majority of respondents had their first illicit drug use in their teenage years. Two-
thirds reported cannabis as their first drug of abuse. Cannabis thus appears to be the 
illicit ‘gateway drug’ in Cape Town. Research has shown that it is the most common 
drug of abuse after tobacco and alcohol among high school students in Cape Town 
(Plüddemann et al, 2010). This might not be unrelated to the fact that South Africa is 
a large producer of cannabis, thus making it highly available and accessible 
(UNODC, 2009). 
Glasner-Edwards et al (2010) had earlier reported the average frequency of 
methamphetamine use among individuals dependent on methamphetamine as 12 
days per month. In the current study, only about half of the respondents used 
methamphetamine on a daily basis. It is not unusual to find individuals who use 















methamphetamine. It may be that the ‘binge and crash’ pattern of use is common 
among this group of weekend users. 
The pattern of methamphetamine use found in this study is characteristic of a 
sample drawn from treatment centres. The majority had used an average of one 
gram per week for more than three years. They equally lacked the capacity to 
abstain from using for up to six months. 
6.3 PSYCHIATRIC COMORBIDITY 
The prevalence of psychiatric morbidity amongst the study population was found to 
be 38.3%. This is higher than both the lifetime and 12-month prevalence of 
psychiatric disorders among the general population of South Africa.  In a large-scale 
population-based study of common mental disorders in the South Africa, the lifetime 
prevalence of psychiatric disorders was found to be 30.3% while the 12-month 
prevalence was 16.5% (Herman et al, 2009; Williams et al, 2008). 
The observed high rate of psychiatric disorders in the study population is consistent 
with the findings of a previous study (Glasner-Edwards et al, 2010). This suggests 
that psychiatric disorders are quite common among individuals dependent on 
Methamphetamine. Although the rate in the current study is slightly lower rate than 
the 48.1% prevalence rate reported by Glasner-Edwards et al (2010), differences in 
sample size, study population and diagnostic methods could have contributed to this 
discrepancy. Nonetheless, this rate still falls within the mid-range of estimated 
prevalence rates among individuals dependent on similar stimulants such as 
cocaine, which is between 21% and 73% (Rounsaville et al, 1991; Weiss et al, 















6.3.1 PREVALENCE AND PATTERN OF PSYCHIATRIC DISORDERS 
Prevalence rates were 18.3%, 13.3% and 6.7% for mood, psychotic and anxiety 
disorders respectively. Prior reports from clinical samples of methamphetamine 
users had equally shown that psychiatric co-morbidity was largely accounted for by 
mood disorders, psychotic disorders and anxiety disorders (Glasner-Edwards et al, 
2010).  
Mood disorders were the commonest psychiatric disorders in the current study. More 
than half of those with mood disorders had ‘Bipolar disorder Not Otherwise 
Specified’. This was characterised by intermittent hypomanic episodes. Though it 
might be a rarely reported finding, methamphetamine use is known to cause 
hypomanic symptoms (Lee, 2007) significant enough to meet this diagnostic rubric. 
This is especially true when structured diagnostic instruments such as the SCID is 
utilised. 
The substance induced mood disorders observed in this study were primarily 
substance induced depression. Out of the total study population, 3.3% had 
substance induced depression. This parallels the work of Salo et al (2010) which 
reported 10.6% prevalence of substance induced mood disorder (with depressive 
features) in a larger sample of methamphetamine dependent subjects. The use of 
methamphetamine can result in depressive symptoms not only in the aftermath of 
the use episode, but months thereafter (Zweben et al, 2004). It is not clear if these 
depressive symptoms are part of ‘Methamphetamine Withdrawal Syndrome’ or 
constitute an independent entity. Two previous studies (Zorick et al, 2010; McGregor 
et al, 2005) had reported acute (7-10days) and sub-acute (second and third weeks) 















Syndrome’. Nonetheless, in a study of methamphetamine-dependent individuals 
entering psychosocial treatment, depressive symptoms declined during the course of 
treatment (Glasner-Edwards et al, 2009). Symptoms reduced among those who 
abstained from methamphetamine during treatment relative to those who used; 
abstainers shifted from clinically relevant symptom levels at baseline to the normal or 
minimal symptom range at discharge.   
One out of every seven respondents in this study had a psychotic disorder. The 
observed 13.3% prevalence rate of psychotic disorders is consistent with the findings 
of a recent study (Glasner-Edwards et al, 2010) which reported psychotic disorders 
as common amongst individuals dependent on methamphetamine. In addition, in a 
study of inpatients admitted for substance dependence in Sweden, 31.5% of 
methamphetamine users met criteria for psychotic diagnosis (Dalmau et al, 1999).  
Psychosis represents a significant mental health problem in relation to 
methamphetamine use (Lee et al, 2007). In considering a mechanism by which 
elevated psychotic disorders in methamphetamine dependent populations may be 
explained, there is a need to separate substance–related from substance–
independent underlying aetiologies of psychosis.  
Half of the psychotic disorders, constituting 6.7% of the total psychiatric co-morbidity 
in this study were due to Paranoid Schizophrenia. This may be due to the fact that 
methamphetamine use not only triggers psychotic relapse in individuals with 
schizophrenia but can initiate onset of schizophrenic illness in predisposed 
individuals (Lee et al, 2007).  
The prevalence of methamphetamine-induced psychoses in this study was 3.3% and 















(McKetin et al, 2006; Newton et al, 2004), they were ‘Brief psychotic disorders which 
occurred transiently and subsided within a week of abstinence. Methamphetamine-
induced psychosis has been associated with chronic high-dose use of 
methamphetamine, as well as the use of potent forms such as ‘crystal meth’ (Lee et 
al, 2007). Majority of the participants in the current study had used an average of 
one gram per week of ‘crystal meth’ for more than three years. Therefore, the 
observed low prevalence of this substance-induced psychosis in comparison to 
previous studies (Shoptaw et al, 2003; McKetin et al, 2006), may be due to 
differences in methodology and sample. The study by Shoptaw et al (2003), for 
example , was carried out among gay and bisexual men while McKetin et al (2006) 
made psychiatric diagnoses using the Brief Psychiatric Rating scale. 
Anxiety is one of the common psychiatric symptoms reported among 
methamphetamine users (Glasner-Edwards et al, 2010b; Zweben et al, 2004). In the 
current study, the prevalence of anxiety disorders was 6.7%; no substance-induced 
anxiety disorder was found. Two previous studies (Salo et al, 2010; Shoptaw et al, 
2003), had inferred that anxiety disorders tend to be independent disorders rather 
than substance-induced among methamphetamine users. Rates of substance-
induced anxiety disorders were lower compared to that of primary anxiety disorders 
in the two studies. In addition, the modest sample size of this current study possibly 
contributed to the absence of substance-induced anxiety disorders in the study.    
6.3.2 RISK FACTORS FOR PSYCHIATRIC COMORBIDITY 
Risk factors for psychiatric co-morbidity identified in this study include being male, 
younger age and previous psychiatric history. Different researchers had reported 















among substance-using population. Katz et al (2008) reported that dual-diagnosis 
patients were often males. On the other hand, a study of psychiatric morbidity and 
gender differences among methamphetamine users found that women commonly 
experienced mental health disturbances than their male counterparts (Lin et al, 
2004). Important methodological differences such as sample size and study setting 
may be responsible for the reported findings of the latter and this current study. For 
example, the latter was conducted in a forensic setting.  
An inversely proportional relationship was found between age and psychiatric co-
morbidity; younger individuals had an increased risk of psychiatric co-morbidity.  A 
similar observation was noted by Katz et al (2008). This possibly reflects the 
vulnerability of the younger person; effects on developmental processes and 
plasticity of the young brain to the effects of drugs. In this study, more than 80% of 
the respondents were younger than 35 years of age, had their first drug use as 
teenagers and had used methamphetamine for more than 3 years. These may have 
contributed to the observed high prevalence of psychiatric co-morbidity. 
Previous psychiatric history was found to be independently associated with 
psychiatric co-morbidity among individuals dependent on methamphetamine. This is 
consistent with a previous report (Lee et al, 2007). The use of methamphetamine 
may not only induce new psychiatric disorders but exacerbate pre-existing disorders. 
Therefore, individuals with previous psychiatric history are particularly vulnerable to 
further mental health disturbances when they use methamphetamine. Also, it is 
plausible that psychiatrically ill individuals are vulnerable to methamphetamine use 
















6.4 READINESS FOR CHANGE 
Sixty-percent of the respondents were at the stage of ‘Taking steps’. This proportion 
of motivated individuals is consistent with what would have been expected for a 
sample of individuals drawn from treatment centres at various stages of therapy.  
6.4.1 READINESS FOR CHANGE AND PSYCHIATRIC COMORBIDITY 
Few studies had examined the relationship between readiness for change and 
psychiatric co-morbidity among substance dependent cohorts. Carosella et al (1999) 
reported that psychiatric co-morbidity negatively impacts on readiness for change 
among individuals dependent on nicotine. On the other hand, a critical review of the 
literature by Heffner et al (2007) showed that psychiatric co-morbidity is not a 
consistent predictor of readiness for change.  
In this study, psychiatric co-morbidity showed no association with readiness for 
change other than Recognition of the drug problem. Respondents with current 
psychiatric co-morbidity had significant lower scores on the SOCRATES’ dimension 
of ‘Recognition’ compared to those without psychiatric co-morbidity (p = 0.01). This 
significant reduction in the recognition of the drug problem might be due to intra-
psychic experiences or impaired judgement associated with psychiatric disorders. It 
does appear that beyond this stage of recognition, psychiatric co-morbidity had no 
significant associations with the other stages of readiness for change. 
As instructive as this may be for treatment planning, the finding should be 
considered in the context of the limitations of this study. First, the respondents were 
volunteers; they could have been predisposed to change. Second, a modest sample 















policies of the participating treatment centres precluded individuals with florid 
psychiatric symptoms. Therefore, volunteers with co-morbid psychiatric disorders 
had their symptoms in remission.  
6.4.2 FACTORS ASSOCIATED WITH READINESS FOR CHANGE 
Recognition: 
Recognition of the drug problem was found to correlate positively with quantity of 
methamphetamine used per week. This suggests that users of large quantity of 
methamphetamine per week were more likely to recognize the severity of their drug 
problem and the consequent need to do something about that problem. This shares 
some similarities with the findings of a previous study in which recognition was found 
to be positively related to frequency of heroin use (Gossop et al, (2007).  
Other important associations with the recognition stage of readiness for change 
found in this study include: gender, religious affiliation and previous psychiatric 
history.  
Females had significantly higher scores on Recognition compared to their male 
counterparts (p = 0.04). This implies that females are more aware of problems 
related to their methamphetamine addiction. The observed association of gender 
with Recognition is at variance with the findings of a multi-centre study of drug users 
in Malaysia (Fauziah et al, 2011). The latter reported no difference between the 
genders with respect to Recognition. However, considering earlier reported barriers 
to alcohol and drug treatment for women in Cape Town (Myers et al, 2011; Myers et 
al, 2009), it may be that females who eventually make it to drug rehabilitation centres 















that, the better recognition of methamphetamine problems by females observed in 
this study may be because more males had psychiatric co-morbidity which impacted 
negatively on Recognition.  
Affiliation to a religious group was also observed to be significantly associated with 
recognition of drug-related problems. Respondents with no religious affiliation scored 
lower on recognition in comparison with those that have religious affiliation; be it 
Christianity or Islam (p = 0.02). Although religious and spiritual beliefs were found to 
be associated with better treatment outcome among a group of drug users in the 
United States (Heinz et al, 2007), little is known about the relationship between 
religious affiliation and stages of change. It is probable that religion facilitates 
conscious awareness of drug related problems by creating cognitive dissonance in 
the individual. 
Similar to the relationship between current psychiatric morbidity and the Recognition 
stage mentioned above, previous psychiatric history equally had a negative impact 
on ability to recognise methamphetamine-related problems. Respondents with 
previous psychiatric history had significantly lower recognition score (p = 0.02).  
Ambivalence: 
Factors found to be related to Ambivalence include treatment duration and leisure 
activities. A significant negative correlation was observed between treatment 
duration and ambivalence. This shows that with longer treatment duration, the level 
of doubt to change reduces. Similarly, previous studies have reported better 
treatment outcome of addiction disorder with longer duration of treatment (Hubbard 
















The nature of leisure activities had significant association with Ambivalence. 
Respondents with drug-related leisure activities scored higher on ambivalence 
compared to those involved in non-drug related leisure activities (p = 0.02). Such an 
observation implies that having alternative non-drug related leisure activities reduces 
ambivalence towards change. This is a logical and common sense relationship that 
is being confirmed by this study. It does mean that contextual factors such as leisure 
time activities contribute to readiness for change. This finding may be of prognostic 
importance in the treatment of methamphetamine dependence. 
Taking steps: 
The duration of methamphetamine use seems to affect the ability to take steps 
towards overcoming the addiction. This is reflected in the significant negative 
correlation between duration of methamphetamine use and Taking steps observed in 
this study. Putting this observation into consideration while planning treatment of 
methamphetamine users may improve therapeutic outcome.   
At the stage of Taking steps, educational level did appear to be influential. 
Interestingly, respondents with lower education level (below matric) had significantly 
higher scores in Taking Steps compared to more educated ones. Amongst a large 
sample of smokers, Velicer and colleagues (1995) discovered that education level 
was negatively associated with stages of change. As the level of education 
increased, they were less likely to stop smoking (Velicer et al, 1995). Nonetheless, 
this finding should be interpreted with due consideration to limitations of the current 


















LIMITATIONS AND STRENGTH 
7.1 LIMITATIONS: 
i. The sample being one drawn from treatment centres limits the extent of 
generalisation of findings to the population of methamphetamine dependent 
individuals within the community. 
ii. The relatively limited sample size and non-random selection of participants. 
iii. The effects of educational level on participants’ responses to the self-
administered instruments cannot be ruled out. More than half of the 
participants did not complete secondary education. 
iv. The study did not report on the relationship between each category of 
psychiatric disorder and readiness for change. Each psychiatric disorder may 
impact differently on readiness for change. 
  
7.2 STRENGTH: 
i. The diagnoses of psychiatric disorders were made using a structured 
diagnostic instrument. 
ii. This study elucidated the patterns of psychiatric co-morbidity among the study 
population. Independent psychiatric disorders were separated from substance 
induced disorders. 
iii. Pertinent findings from this study may add to the body of literature in the field 
of addiction psychiatry from Africa. This may be a basis for further studies. 


















Methamphetamine abuse is a major problem among the ‘coloured’ population of 
Cape Town. Most of the respondents had their first drug use as teenagers. They left 
school before the matriculation class and were mostly unemployed. Those 
dependent on methamphetamine experience psychiatric disorders more than the 
general population. 
In this study, the prevalence of psychiatric co-morbidity was 38.3%. This high 
prevalence rate is a reflection of the vulnerability of these individuals to psychiatric 
disorders, either from exacerbation of pre-existing disorder or induction of new ones. 
Mood disorders were the most frequent, followed by psychotic and anxiety disorders. 
Bipolar disorder Not Otherwise Specified (intermittent hypomanic episodes) was the 
commonest mood disorder. Among those with psychotic disorders, Paranoid 
schizophrenia was the commonest. The male gender and previous psychiatric 
history were risk factors for current psychiatric co-morbidity. Also, younger 
methamphetamine users had higher risks of psychiatric co-morbidity. 
Current psychiatric co-morbidity and previous psychiatric history adversely affected 
recognition of the drug problem. Beyond the stage of recognition, no relationship was 
found between psychiatric co-morbidity and readiness for change among individuals 
dependent on methamphetamine.  
Females were more aware of problems related to their methamphetamine addiction. 
Also, individuals with religious beliefs or affiliation recognised drug problems better. 















Having alternative non-drug related leisure activities equally reduced ambivalence to 
change.  
Lastly, the longer the duration of methamphetamine use, the more difficult it is to 





































To reduce the scourge of methamphetamine addiction and its mental health 
consequences in Cape Town, primary prevention strategies should target teenagers. 
Broad-based school-based drug policies should be actively developed and 
promoted. 
In the light of the observed high prevalence of psychiatric disorders among 
individuals dependent on methamphetamine, there is a need to train drug 
counsellors to be more adept at identifying mental health symptoms. Those with co-
morbid psychiatric disorders may not necessarily b  excluded from motivational 
therapy sessions. Rather an integrated model of care addressing both substance 
use disorders and psychiatric co-morbidity should be instituted in drug rehabilitation. 
This would mean a review of the current admission policy into rehabilitation centres 
and employment of psychiatry personnel in these centres to facilitate integrated care. 
Furthermore, as an important component of effective treatment planning, counsellors 
might find it helpful to identify the duration of drug use and the stage of change which 
characterise each patient. Based on these, individualised strategies or programmes 
to enhance readiness for change among patients could be recommended. 
Also, life skills training should focus on substitution of leisure time with non-drug 
related activities. This would reduce the ambivalence towards change, bolster 















Lastly, there is a need for more studies on readiness for change and mental health of 
individuals dependent on methamphetamine in Western Cape. Such studies should 
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PARTICIPANTS’ INFORMATION SHEET AND CONSENT FORM 
Title of the Research:  
Psychiatric Morbidity and Readiness for change: A study of Methamphetamine 
dependent subjects in Cape Town. 
Dear Participant 
You are being invited to take part in a research project. Please take some time to 
read the information presented below, which will explain the details of this project. 
You can ask the doctor questions about any part of this project that you do not fully 
understand.  
What is the study about? 
The study is aimed at evaluating psychiatric disorders and readiness for change 
among individuals using Methamphetamine in Cape Town. 
What is expected of you if you agree to participate? 
You will be expected to provide answers to questions like your age, marital status, 
religion, employment status, drug habits and attempts at rehabilitation. 
Questionnaires assessing your level of motivation and severity of addiction would be 
administered. You will equally benefit from a structured psychiatric interview.     
Confidentiality: 
The information collected from you will be treated in absolute confidence. No part or 
whole of such information shall be divulged to anybody except the investigators. 
Your Participation is entirely voluntary:  
Your participation in this study is voluntary. You may withdraw at any time of the 
















INFORMED CONSENT FORM 
                                                                                                                                                
In order to participate in this research study, it is necessary that you give your 
informed consent. 
By signing this informed consent form you are indicating that you understand the 
nature of the research study and that you agree to participate in the research. Please 
consider the following points before signing: 
 I understand that I am participating in a research; 
 All the terms of this consent have been explained to me in a language that I 
understand; 
 I am aware that the study to be carried out would not harm me in anyway; 
 I have been assured that the information on me shall be kept in strict 
confidence;                      
 I understand that my participation in this research is voluntary, and that I may 
refuse to participate further at any time without having to offer an explanation. 
By signing this form I am stating that I am 18 years of age or older, and that I 
understand the above information and consent to participate in this study. 
 
……………………………                                    ……………………………        
Name of participant                          Name of researcher 
……………………………                                    ……………………………        





















































































































































F= ANOVA (Analysis of Variance). 
t = t-test. 

























Test df P value 









































Pattern of use 
Twice a week or 
Weekends 





















F= ANOVA (Analysis of Variance). 
t = t-test. 







































































































F= ANOVA (Analysis of Variance). 
t = t-test. 




























Test df P value 
Leisure activities 
Drug related 























t = t-test. 





































t = t-test. 







































































































































F= ANOVA (Analysis of Variance). 
t = t-test. 




















 Table B2: Ambivalence and Methamphetamine use 
 
Variables Ambivalence  
Mean 
Score 
Test df P value 



































Pattern of use 
Twice a week or 
Weekends 

















F= ANOVA (Analysis of Variance). 
t = t-test. 














































































































F= ANOVA (Analysis of Variance). 
t = t-test. 

























Table B4: Ambivalence and Social Activities 
 




Test df P value 
Leisure activities 
Drug related 























t = t-test. 




Table B5: Ambivalence and Previous Psychiatric History 
 































t = t-test. 



















Table C1: Taking steps and Socio-demographic Characteristics 
 

























































































































F= ANOVA (Analysis of Variance). 
t = t-test. 




















 Table C2: Taking steps and Methamphetamine use 
 
Variables Taking Steps 
Mean 
Score 
Test df P value 






































Pattern of use 
Twice a week or 
Weekends 





















F= ANOVA (Analysis of Variance). 
t = t-test. 
























Table C3: Taking steps and Methamphetamine Treatment/Abstinence 























































































F= ANOVA (Analysis of Variance). 
t = t-test. 























Table C4: Taking steps and Social Activities 
 
Variables Taking Steps 
Mean 
Score 
Test df P value 
Leisure activities 
Drug related 
























t = t-test. 




Table C5: Taking steps and Previous Psychiatric History 
 
Variables Taking Steps 
Mean 
Score 































t = t-test. 


















Table D: Correlations 
Test variables 
                 → 

























 SDS  Score  Correlation 
Coefficient 
  1.000 -0.016 0.094 -0.127 -0.066 -0.052 0.058 -0.010 
Sig. (2-tailed) . 0.902 0.474 0.333 0.618 0.694 0.659 0.939 
N 60 60 60 60 60 60 60 60 
Recognition  Correlation 
Coefficient 
-0.016 1.000 0.055 0.195 -0.091 0.045 0.313
*
 0.042 
Sig. (2-tailed) 0.902 . 0.679 0.135 0.487 0.730 0.015 0.752 
N 60 60 60 60 60 60 60 60 
Ambivalence  Correlation 
Coefficient 
0.094 0.055 1.000 -0.602
**
 -0.119 0.092 -0.086 -0.339
**
 
Sig. (2-tailed) 0.474 0.679 . 0.000 0.364 0.486 0.512 0.008 
N 60 60 60 60 60 60 60 60 









Sig. (2-tailed) 0.333 0.135 0.000 . 0.672 0.021 0.003 0.206 
N 60 60 60 60 60 60 60 60 
Age  Correlation 
Coefficient 
-0.066 -0.091 -0.119 -0.056 1.000 0.040 0.088 -0.012 
Sig. (2-tailed) 0.618 0.487 0.364 0.672 . 0.762 0.505 0.925 
N 60 60 60 60 60 60 60 60 




-0.052 0.045 0.092 -0.297
*
 0.040 1.000 0.111 0.062 
Sig. (2-tailed) 0.694 0.730 0.486 0.021 0.762 . 0.400 0.640 
N 60 60 60 60 60 60 60 60 
‘Tik’ Quantity 









 0.088 0.111 1.000 0.018 
Sig. (2-tailed) 0.659 0.015 0.512 0.003 0.505 0.400 . 0.891 










 0.166 -0.012 0.062 0.018 1.000 
Sig. (2-tailed) 0.939 0.752 0.008 0.206 0.925 0.640 0.891 . 
N 60 60 60 60 60 60 60 60 
*. Correlation is significant at the 0.05 level (2-tailed).                                                   

















                                                                                Study ID: ----------------- 
Section A: 
1. Gender :    Male  .............                                   Female ................. 
2. Age :  ........................ 
3. Race  :        i. Black  
                       ii. White 
                       iii. Coloured 
                        iv. Asians                                   others (specify)................. 
4. Religion........................................ 
    Would you describe yourself as a religious person?    Yes..........          No......... 
5. Marital status:        i. Single 
                                   ii. Married 
                                   iii. Co-habiting 
                                   iv. Widowed 
                                   v. Divorced 
                                   vi. Separated 
6. Do you have children?   Yes .......                                          No ......          
     If Yes, how many? ............................... 
7. Where do you live? ......................................... 
8. What term best describes the kind of neighbourhood in which you live? 
                            i. Suburban 
                            ii. Urban 
                            iii. Township 
                            iv. Intermediate 















10. What is your highest level of education (highest grade completed)?....................      
11. Employment status:   i. Employed 
                                         ii. Unemployed 
                                         iii. Student 
                                         iv. Others    (specify) 
     If employed, what kind of job do you do? ............................................................... 
12. Monthly income ............................................. 
 
Section B: 
13. What was your first drug of abuse (apart from Alcohol and Tobacco)? .................. 
      Name the first 2 drugs in order of usage (i................... 
                                                                      (ii.................... 
14. How old were you when you first used drug? ........................... 
15. How long have you been using ‘Tik’ ? .............................. 
16. How much do you spend on ‘Tik’ on a weekly basis? .................... 
17a.What quantity of ‘Tik’ do you use on a weekly basis? (i.e. ‘straws’, grams, 
‘packs’) ........................ 
17b. How often do you use ‘Tik’ per week? (i.e. number of days per week) 
............................................................................. 
18. Type of current ‘Tik’ treatment:     i. In-patient Rehab 
                                                           ii.Out-patient Rehab 
 
19. Reason for current ‘Tik’ treatment:  i. Voluntary 
                                                              ii. Mandated / Compulsory (e.g. by court)  
 
















21. Have you had any previous treatment for ‘Tik’ abuse?   Yes.......            No....... 
      If Yes, which type:              i. In-patient Rehab 
                                                 ii. Out-patient Rehab 
                                                 iii. Both in-patient and out-patient Rehab 
22. How many attempts at rehabilitation have you had in the past? ........................... 
23. What was your longest period of abstinence from ‘Tik’ as a consequence of 
treatment?.................................. 
24. What was your longest period of voluntary abstinence from ‘Tik’ (not as a 
consequence of treatment)? ..................................... 
 
Section C: 
25. Have you ever been diagnosed to have a psychiatric illness in the past?           
Yes............                                         No.......... 
If Yes, when was the first time you had a psychiatric illness? (Specify month and 
year) ............................................................. 
26. Has anyone in your family had a psychiatric illness not related to drug abuse? 
          Yes...............                                 No.............         
If Yes, who?  (e.g. Father, Brother, Aunt, Cousin, etc) ................................... 
 
Section D: 
27. How have you been spending your free time? ........................................... 
 
28. With whom do you spend most of your free time:   i. Family 
                                                                                      ii. Friends 

















Severity of Dependence Scale (SDS) 
 
             In the past twelve months: 
            1. Did you ever think your Tik use was out of control? 
                                         Never or almost never              0  
                                         Sometimes                                1  
                                         Often                                         2  
                                         Always or nearly always           3  
            2. Did the prospect of missing a smoke of Tik make you very anxious or worried?  
                                         Never or almost never               0  
                                         Sometimes                                1  
                                         Often                                         2  
                                         Always or nearly always           3  
            3. Did you worry about your Tik use?  
                                        Not at all                                     0  
                                        A little                                         1  
                                       Quite a lot                                   2  
                                       A great deal                               3  
            4. Did you wish you could stop?  
                                       Never or almost never                0  
                                      Sometimes                                  1  
                                     Often                                            2  
                                     Always or nearly always              3  
            5. How difficult would you find it to stop or go without Tik ?  
                                     Not very difficult                           0  
                                    Quite difficult                                1  
                                    Very difficult                                 2  
                                 Impossible                               3  
 
 
